申请人:Neurotune AG
公开号:EP2620149A2
公开(公告)日:2013-07-31
The use of dimiracetam in the treatment of chronic pain chronic pain induced by osteoarthritis, rheumatoid arthritis or autoimmune osteoarthrosis forms is disclosed. At doses higher than those previously disclosed in relation with its cognition enhancing activity (i.e. amelioration of learning and memory), dimiracetam was able to completely revert hyperalgesia or allodynia associated with several animal models of chronic pain. Dimiracetam showed high activity in painful conditions caused by osteoarthritis. In addition, dimiracetam was devoid of toxicity even at doses 10-fold higher than the highest therapeutic dose. The possibility of treating such debilitating pathologies with a highly effective and essentially non-toxic compound is therefore disclosed.
本研究公开了地米拉西坦在治疗由骨关节炎、类风湿性关节炎或自身免疫性骨关节病引起的慢性疼痛中的应用。在剂量高于之前披露的与认知增强活性(即改善学习和记忆)相关的剂量时,地米拉西坦能够完全恢复与几种慢性疼痛动物模型相关的痛觉过度或异动症。在骨关节炎引起的疼痛方面,地米拉西坦显示出很高的活性。此外,即使使用比最高治疗剂量高10倍的剂量,地米拉西坦也不会产生毒性。因此,这种高效且基本无毒的化合物可用于治疗此类使人衰弱的病症。